Literature DB >> 23181516

Efficient solution-phase synthesis of 4,5,7-trisubstituted pyrrolo[3,2-d]pyrimidines.

Weihe Zhang1, Jing Liu, Michael A Stashko, Xiaodong Wang.   

Abstract

We have developed an efficient and robust route to synthesize 4,5,7-trisubstituted pyrrolo[3,2-d]pyrimidines as potent kinase inhibitors. This solution-phase synthesis features a SNAr substitution reaction, cross-coupling reaction, one-pot reduction/reductive amination and N-alkylation reaction. These reactions occur rapidly with high yields and have broad substrate scopes. A variety of groups can be selectively introduced into the N5 and C7 positions of 4,5,7-trisubstituted pyrrolopyrimidines at a late stage of the synthesis, thereby providing a highly efficient approach to explore the structure-activity relationships of pyrrolopyrimidine derivatives. Four synthetic analogs have been profiled against a panel of 48 kinases and a new and selective FLT3 inhibitor 9 is identified.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23181516      PMCID: PMC3724770          DOI: 10.1021/co300106f

Source DB:  PubMed          Journal:  ACS Comb Sci        ISSN: 2156-8944            Impact factor:   3.784


  11 in total

1.  Comparison of on-chip and off-chip microfluidic kinase assay formats.

Authors:  Jude Dunne; Holly Reardon; Vy Trinh; Ella Li; Javier Farinas
Journal:  Assay Drug Dev Technol       Date:  2004-04       Impact factor: 1.738

2.  Two simple and generic antibody-independent kinase assays: comparison of a bioluminescent and a microfluidic assay format.

Authors:  Antje Pommereau; Everard Pap; Aimo Kannt
Journal:  J Biomol Screen       Date:  2004-08

3.  A chemogenomic analysis of the human proteome: application to enzyme families.

Authors:  Paul Bernasconi; Min Chen; Scott Galasinski; Ioana Popa-Burke; Anna Bobasheva; Louis Coudurier; Steve Birkos; Rhonda Hallam; William P Janzen
Journal:  J Biomol Screen       Date:  2007-10

4.  Second generation transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase.

Authors:  Gary B Evans; Richard H Furneaux; Dirk H Lenz; Gavin F Painter; Vern L Schramm; Vipender Singh; Peter C Tyler
Journal:  J Med Chem       Date:  2005-07-14       Impact factor: 7.446

5.  Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.

Authors:  David J Calderwood; David N Johnston; Rainer Munschauer; Paul Rafferty
Journal:  Bioorg Med Chem Lett       Date:  2002-06-17       Impact factor: 2.823

6.  Discovery of pyrrolopyrimidine inhibitors of Akt.

Authors:  James F Blake; Nicholas C Kallan; Dengming Xiao; Rui Xu; Josef R Bencsik; Nicholas J Skelton; Keith L Spencer; Ian S Mitchell; Richard D Woessner; Susan L Gloor; Tyler Risom; Stefan D Gross; Matthew Martinson; Tony H Morales; Guy P A Vigers; Barbara J Brandhuber
Journal:  Bioorg Med Chem Lett       Date:  2010-08-13       Impact factor: 2.823

Review 7.  FLT3 inhibitors for the treatment of acute myeloid leukemia.

Authors:  Peter H Wiernik
Journal:  Clin Adv Hematol Oncol       Date:  2010-06

8.  N-phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases.

Authors:  Yuya Oguro; Naoki Miyamoto; Terufumi Takagi; Kengo Okada; Yoshiko Awazu; Hiroshi Miki; Akira Hori; Keiji Kamiyama; Shinichi Imamura
Journal:  Bioorg Med Chem       Date:  2010-08-25       Impact factor: 3.641

9.  Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

Authors:  Mark E Flanagan; Todd A Blumenkopf; William H Brissette; Matthew F Brown; Jeffrey M Casavant; Chang Shang-Poa; Jonathan L Doty; Eileen A Elliott; Michael B Fisher; Michael Hines; Craig Kent; Elizabeth M Kudlacz; Brett M Lillie; Kelly S Magnuson; Sandra P McCurdy; Michael J Munchhof; Bret D Perry; Perry S Sawyer; Timothy J Strelevitz; Chakrapani Subramanyam; Jianmin Sun; David A Whipple; Paul S Changelian
Journal:  J Med Chem       Date:  2010-11-24       Impact factor: 7.446

10.  Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists.

Authors:  M H Norman; N Chen; Z Chen; C Fotsch; C Hale; N Han; R Hurt; T Jenkins; J Kincaid; L Liu; Y Lu; O Moreno; V J Santora; J D Sonnenberg; W Karbon
Journal:  J Med Chem       Date:  2000-11-02       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.